Efficacy of erlotinib as first-line maintenance therapy in patients with locally advanced or metastatic nonsmall cell lung cancer who have not experienced disease progression or unacceptable toxicity during chemotherapy

BACKGROUND: First-line maintenance with erlotinib in nonsmall cell lung cancer (NSCLC) patients without progression after four cycles of chemotherapy was well tolerated and significantly prolonged progression-free survival (PFS) compared with placebo. AIM AND DESIGN: This open-label, single arm, Pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Rajappa, Senthil, Doval, Dinesh Chandra, Biswas, Jaydip, Patil, Shekar, Somani, Naresh, Srinivasan, Sankar, Bondarde, Shailesh, Palwe, Nitin S., Swarup, Binay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
ORIGINAL ARTICLE: Lung Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5379883/
https://www.ncbi.nlm.nih.gov/pubmed/28413785
http://dx.doi.org/10.4103/2278-330X.202573

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5379883/
https://www.ncbi.nlm.nih.gov/pubmed/28413785
http://dx.doi.org/10.4103/2278-330X.202573

Ejemplares similares